Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Preventive therapy for HIV-associated tuberculosis

Durovni, Betinaa; Cavalcante, Solangeb

Current Opinion in HIV and AIDS: November 2018 - Volume 13 - Issue 6 - p 507–511
doi: 10.1097/COH.0000000000000504
TUBERCULOSIS AND HIV: Edited by Richard E. Chaisson and Haileyesus Getahun
Buy

Purpose of review Tuberculosis (TB) remains the leading cause of death in people living with HIV (PLHIV) despite the achievements in antiretroviral therapy coverage. TB preventive therapy (TPT) has proved efficacy but has been neglected and poorly implemented. We reviewed recent publications and guidelines about TPT in PLHIV.

Recent findings High-quality studies showed that TPT has a durable effect, over 5 years, preventing TB and all-cause mortality. There is new evidence showing the noninferiority of shorter, rifamycin-based regimens of TPT increasing the options for treatment. Recent studies describing robust implementation in different settings showed promising results for feasibility, tolerance, retention, and cost-effectiveness. New WHO recommendations, unifying previous versions, have been released to guide countries implementation.

Summary New evidence support the scale up of TPT for PLHIV globally, further studies are needed to bring more evidence for specific populations, like pregnant women and for drug–drug interactions with antiretroviral agents.

aCenter for Strategic Studies, Fiocruz and Instituto de Doenças do Torax Federal University of Rio de Janeiro, UFRJ

bEvandro Chagas National Institute of Infectious Diseases – Fiocruz, Rio de Janeiro, Brazil

Correspondence to Betina Durovni, MD, PhD, Center for Strategic Studies, Fiocruz and Federal University of Rio de Janeiro, UFRJ, Av. Brasil, 4036 – Prédio da Expansão – 10 Andar – Manguinhos, 21040-361 Rio de Janeiro, RJ, Brazil. E-mail: betina.durovni@fiocruz.br

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.